MedTrace Logo

CAN1012 in Pre-Malignant DCIS and LCIS

NCT07408856 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-23

No results posted yet for this study

Summary

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Conditions

  • Ductal Carcinoma in Situ
  • Lobular Carcinoma in Situ

Interventions

DRUG

CAN1012

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

Sponsors & Collaborators

  • CanWell Pharma Inc.

    collaborator INDUSTRY

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Sasha Stanton, MD, PhD · Providence Health & Services

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2030-05-31
Completion
2035-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408856 on ClinicalTrials.gov